Login / Register Order My Items
Contact Us
800.227.0627
Contact Us Quote Order Login / Register

Bioorthogonal Conjugation for Oligonucleotide Drug Conjugates (ODCs)

Click chemistry (SPAAC, IEDDA) for site-specific small-molecule payload attachment to siRNA and ASO.

Bioorthogonal click chemistry enables precise attachment of small-molecule payloads, ligands, and probes to therapeutic oligonucleotides such as siRNA and ASO using highly selective reactions including SPAAC (azide–DBCO) and tetrazine–TCO IEDDA.

Discuss your handle + payload Compare click reactions
Talk to a chemist Request a quote
Overview Related Reaction options Handle selection Placement guidance Workflow Analytics Applications FAQ Contact

Overview: bioorthogonal conjugation for ODCs

Bioorthogonal conjugation is a cornerstone strategy for constructing modern oligonucleotide–drug conjugates (ODCs). These reactions employ mutually selective chemical handles such as azide–DBCO (SPAAC) or tetrazine–TCO (IEDDA) that react rapidly and specifically in aqueous environments while remaining inert toward native biomolecules including proteins, lipids, and nucleic acids.

In therapeutic oligonucleotide engineering, bioorthogonal chemistry enables the controlled installation of small-molecule payloads, delivery ligands, fluorophores, and other functional modules at defined positions on siRNA, ASO, DNA, or RNA constructs. Because these reactions proceed without interfering with biological functional groups, they support site-specific conjugation, reproducible product profiles, and modular assembly of complex therapeutic architectures.

For oligonucleotide–drug conjugates, bioorthogonal reactions enable:

Bioorthogonal conjugation is widely used in the development of next-generation RNA therapeutics, including siRNA conjugates, antisense oligonucleotide drug conjugates, and modular nucleic-acid delivery platforms.

Site-specific loading

Defined conjugation at 5′/3′/internal positions with controlled stoichiometry.

Cleaner impurity profile

Reduces side products vs non-selective coupling in mixed functional group environments.

Orthogonal builds

Dual labeling or multi-component architectures using non-cross-reacting chemistries.

Bioorthogonal click chemistry for oligonucleotide drug conjugates showing azide-DBCO SPAAC and tetrazine-TCO IEDDA attachment of small-molecule payloads to siRNA and ASO

Oligonucleotide conjugate with 5′ Pam3 and 3′ BODIPY installed using azide–DBCO bioorthogonal conjugation.

Why bioorthogonal chemistry is used for ODC design

High selectivity in water

Reactions proceed efficiently in aqueous buffers without broad electrophile/nucleophile coupling.

  • Improves reproducibility
  • Reduces heterogeneous products
  • Supports scale-up
Defined stoichiometry

Single-site conjugation helps control loading and simplifies analytics.

  • Clearer HPLC profiles
  • Better lot-to-lot control
  • Screening-ready variant sets
Orthogonal architectures

Pair non-cross-reacting chemistries for dual payloads, labels, or delivery ligands.

  • SPAAC + IEDDA combinations
  • Sequential conjugations
  • Modular design

Bioorthogonal reaction options for oligonucleotide conjugation

The best reaction depends on payload sensitivity, required kinetics, copper tolerance, and whether you need one-step vs staged assembly.

Reaction Handle pair Strengths Watch-outs
SPAAC (copper-free click) Azide + DBCO / cyclooctyne Therapeutic-friendly; aqueous-compatible; broad adoption for siRNA/ASO conjugates Bulky cyclooctynes can influence hydrophobicity; placement/spacer tuning may be needed
IEDDA (tetrazine ligation) Tetrazine + TCO / norbornene Very fast kinetics; highly selective; supports orthogonal dual builds Tetrazine stability and payload compatibility must be evaluated; storage/handling constraints
CuAAC (copper-catalyzed click) Azide + alkyne (+ Cu) Robust chemistry; widely used in small-molecule synthesis Copper can damage/modify nucleic acids; copper-free approaches are often preferred

Default recommendation: start with SPAAC (azide–DBCO) for therapeutic oligos unless kinetics or orthogonality requirements favor IEDDA.

Bioorthogonal handles for oligonucleotides

Azide (N3)

Versatile handle for SPAAC or CuAAC workflows.

  • Commonly installed at 5′/3′ termini
  • Pairs with DBCO/cyclooctyne
  • Compatible with aqueous conjugation
DBCO / cyclooctyne

Copper-free partner for azides (SPAAC).

  • Fast copper-free click
  • Bulky/hydrophobic → consider spacers
  • Good general-purpose starting point
Tetrazine & TCO

Ultra-fast IEDDA ligation for staged or orthogonal builds.

  • Very rapid kinetics
  • Orthogonal multi-component designs
  • Evaluate stability and storage constraints

Handle selection checklist

Question Implication
Is copper acceptable? If uncertain, favor SPAAC or IEDDA (copper-free) for therapeutic oligos.
How fast must conjugation be? IEDDA typically offers the fastest kinetics; SPAAC is often sufficient for standard builds.
Is payload hydrophobic? Use spacer engineering and controlled loading to reduce aggregation and improve purification.
Do you need orthogonal dual labeling? Plan non-cross-reacting pairs (e.g., SPAAC + IEDDA) and staged assembly.

Placement guidance for siRNA and ASO conjugates

Placement should preserve the oligonucleotide mechanism while positioning the payload for the desired release/uptake behavior.

Oligo type Common placement approaches Why it’s used
Duplex siRNA Handles often installed on the sense strand (commonly 3′), or at defined termini with spacers. Helps preserve antisense strand loading into RISC; enables screening of placement/spacer effects.
ASO (gapmer / SSO) 5′/3′ terminal handles are common; internal placement is program-dependent. Avoids disrupting RNase H recruitment or steric-block binding; supports clean conjugation chemistry.
Single-strand RNA/DNA Terminal handles with optional spacer tuning. Balances hybridization fidelity with payload sterics and solubility requirements.

Fast screening set: 1 non-cleavable control + 1 cleavable design (if needed) × 2 placements (5′ vs 3′ or strand choice) × 2 spacer lengths.

Practical workflow for bioorthogonal ODC builds

Stage What is done Deliverables
1. Define goal Determine whether the payload requires controlled release or functions as a delivery modifier or tethered activity module. Proposed architecture: placement + spacer + handle pair.
2. Choose handles Select SPAAC (azide–DBCO) or IEDDA (tetrazine–TCO) based on compatibility and kinetics. Handle specifications and conjugation conditions.
3. Assemble Perform aqueous conjugation; monitor conversion and impurity profile. Purified conjugate(s) with defined loading.
4. Purify HPLC/UPLC purification tuned for hydrophobic payloads; collect target fraction. High-purity ODC with QC package.
5. Confirm Identity and purity confirmation using appropriate analytical tools. HPLC trace(s), MS (when compatible), and orthogonal confirmation as needed.

Analytics and QC for bioorthogonal ODCs

HPLC/UPLC

Primary method to assess conversion and purity; hydrophobic payloads may require method tuning.

LC-MS (when compatible)

Confirms mass of the conjugate and, where possible, key species; feasibility is construct-dependent.

Orthogonal confirmation

UV/Vis ratios, gel/CE methods, or other construct-appropriate tools to support identity claims.

Common decision points
  • Conversion: does the click reaction reach the desired completion under mild conditions?
  • Purification: does the payload increase hydrophobicity requiring spacer or method adjustments?
  • Function: does placement preserve RISC loading (siRNA) or RNase H/SSO function (ASO)?

Typical applications

Small-molecule payload oligonucleotide drug conjugates
  • Site-specific payload installation via SPAAC or IEDDA
  • Stable vs cleavable linker comparisons
  • Screening-ready matched variant sets
Delivery conjugates
  • Ligands and uptake modifiers
  • Modular build strategies
  • Orthogonal dual-component designs
Probes & imaging
  • Fluorophore/quencher conjugation
  • Dual-label architectures (SPAAC + IEDDA)
  • Mechanistic trafficking studies

FAQ

Which click chemistry should I start with?

Most programs start with SPAAC (azide–DBCO) because it is copper-free and widely compatible with siRNA/ASO constructs. If you need very fast kinetics or orthogonal dual labeling, consider tetrazine–TCO (IEDDA).

Do I need a cleavable linker with click chemistry?

Not always. Click chemistry describes the conjugation reaction; controlled release depends on your linker architecture. Delivery modifiers often use stable linkers, while cytotoxic payloads may require cleavable/self-immolative designs.

Where should I place the handle on siRNA?

Handles are often placed on the sense strand (commonly 3′) to preserve antisense RISC loading, but the best placement is program-dependent. A small matched set is usually the fastest way to optimize placement and spacer.

How do you confirm conjugation success?

Typical confirmation includes HPLC/UPLC shifts and, when compatible, LC-MS. We can also use orthogonal confirmation (UV/Vis ratios, gel/CE methods) depending on the construct and payload.

More FAQ'sAll FAQ's

Contact & quote request

For the fastest technical review, share: oligo modality/sequence (and strand info for siRNA), the planned bioorthogonal handle (azide/DBCO/tetrazine/TCO), payload structure or catalog number, intended attachment site (5′/3′/internal), and whether you require cleavable release.

Information checklist
  • Oligo format: siRNA / ASO / DNA / aptamer / PNA / PMO
  • Sequence(s) and strand info (for duplex siRNA)
  • Handle on oligo: azide / DBCO / tetrazine / TCO
  • Handle on payload: DBCO / azide / TCO / tetrazine
  • Desired attachment site: 5′ / 3′ / internal
  • Release requirement: stable vs cleavable (and trigger preference)

If you are uncertain, share your payload structure and desired biology. Handle and spacer selection follows from functional group constraints and trafficking requirements.

Commercial & project inquiries
Request a quote Reaction options

Recommended reading

Background on oligonucleotide delivery barriers and modular conjugation chemistries relevant to bioorthogonal ODC designs.

  • Roberts TC, Langer R, Wood MJA. Advances in oligonucleotide drug delivery. Nature Reviews Drug Discovery. 2020.
  • Khvorova A, Watts JK. The chemical evolution of oligonucleotide therapies. Nature Biotechnology. 2017.
  • Juliano RL. The delivery of therapeutic oligonucleotides. Nucleic Acids Research. 2016.
  • Dowdy SF. Overcoming cellular barriers for RNA therapeutics. Nature Biotechnology. 2017.
  • Bargh JD et al. Cleavable linkers in antibody–drug conjugates. Chemical Society Reviews. 2019. (Linker principles that translate to ODC release design.)

Why Choose Bio-Synthesis

Trusted by biotech leaders worldwide for over 45+ years of delivering high quality, fast and scalable synthetic biology solutions.

Greetings Researchers,

Please be advised that any information, guidelines, writeups, and oral/video/graphic content on our website are intended solely as general guidelines.
It is the researcher's sole responsibility to conduct thorough research on the designs of the products intended for their experiments before submitting
their designs to Biosynthesis for review of production feasibility.
Thank you for your understanding.

Quick Links